BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study

  A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of Clinical Microbiology and Infectious Diseases Global Congress.

  April 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report

  After a record low in 2022, the pharma industry in 2023 saw a surprise rebound in productivity following one of its slowest years on record, according to a report from audit firm Deloitte.

  April 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate

  Johnson & Johnson and Addex Therapeutics’ epilepsy hopeful ADX71149 did not meet its primary endpoint of time to reach baseline seizure count in a mid-stage trial, as the partners look to determine the next steps for the program.

  April 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format

  On June 10, the FDA will convene its Peripheral and Central Nervous System Drugs Advisory Committee to discuss the New Drug Application for Lilly’s Alzheimer’s drug.

  April 29, 2024

   · 

  7 min read

   · 

  Heather McKenzie
• 

  FDA

  FDA Approves First Targeted Treatment for WHIM Syndrome

  After laying off staff in 2022 to extend its cash runway, X4 Pharmaceuticals got its drug for the ultra-rare immunodeficiency disease across the finish line on Monday.

  April 29, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Delivery

  The Next Frontier: Industrializing Cell Therapy Manufacturing

  Q&A: Development Scientist at AGC Biologics Sara Morlacchi analyzes the growth of the cell therapy industry and barriers for cost and accessibility.

  April 29, 2024

   · 

  7 min read

   · 

  Sara Morlacchi, Cell Process Development Manager, AGC Biologics
• 

  Drug Development

  Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT

  Citing anonymous sources involved in a Phase III trial, STAT News reported Sunday that MorphoSys’ pelabresib may worsen the risk of progression to acute myeloid leukemia, potentially putting Novartis’ proposed $2.9 billion acquisition at risk.

  April 29, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint

  Ono Pharmaceutical will pay $25.60 per share in an all-cash deal to buy Deciphera Pharmaceuticals for its potential blockbuster oncology drugs and U.S. sales infrastructure, the companies said Monday.

  April 29, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Business

  BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases

  Bristol Myers Squibb’s deal announced Monday will see the pharma pay $65 million upfront to Repertoire Immune Medicines, which will develop autoimmune disease vaccines using its Decode discovery platform.

  April 29, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Policy

  Opinion: High Drug Prices Don’t Translate into More New Medications

  Pharma CEOs claim lifesaving drugs wouldn’t be possible without high prices — an assertion that doesn’t stand up to scrutiny.

  April 29, 2024

   · 

  4 min read

   · 

  Tahir Amin